Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Expenses (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Operating Expenses data on record, last reported at $142.1 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 81.6% year-over-year to $142.1 million; the TTM value through Dec 2025 reached $493.0 million, up 71.72%, while the annual FY2025 figure was $493.0 million, 71.72% up from the prior year.
  • Operating Expenses reached $142.1 million in Q4 2025 per TGTX's latest filing, up from $132.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $142.1 million in Q4 2025 and bottomed at $35.1 million in Q3 2022.
  • Average Operating Expenses over 5 years is $78.3 million, with a median of $75.2 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: tumbled 59.78% in 2022, then surged 85.24% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $95.3 million in 2021, then decreased by 18.52% to $77.6 million in 2022, then fell by 27.27% to $56.5 million in 2023, then surged by 38.58% to $78.2 million in 2024, then skyrocketed by 81.6% to $142.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $142.1 million in Q4 2025, $132.3 million in Q3 2025, and $106.3 million in Q2 2025.